Skip to main content
HCPCS J0179 · Level II · Part B drug

J0179: brolucizumab-dbll (Beovu), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J0179

Billing unit
1 MG
Inj, brolucizumab-dbll, 1 mg
ASP payment limit
$360.439
October 2026; +0.2% vs July 2026
Practitioner MUE
12
MAI 2
OPPS status
SI K
APC 9340
NCCI exposure
no PTP pairs
Coverage articles
1
5 states

TL;DR

HCPCS J0179 is the Level II code for Injection, brolucizumab-dbll, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $360.439 per billing unit, up 0.2% from July 2026. The practitioner MUE allows up to 12 units per date of service (MAI 2), so a full 12-unit day is $4,325.27 at the current limit. Under OPPS it carries status indicator K in APC 9340. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 1 NDC to it, sold as Beovu by Novartis Pharmaceuticals Corporation. 1 Medicare coverage article lists the code across 5 states, including A52451.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J0179 at $360.439 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $359.713 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J0179
QuarterPayment limitPerCoinsurance
October 2026$360.4391 MG20%
July 2026$359.7131 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J0179. Report the NDC in the claim's drug segment and bill the number of J0179 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J0179
NDCDrug nameLabelerPackage sizeBilling units / package
00078-0827-60BeovuNovartis Pharmaceuticals Corporation0.05 × 16

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for J0179. For practitioners the limit is 12 units per date of service with adjudication indicator 2, a date-of-service policy edit: the limit reflects CMS policy and units above it deny even if split across lines; appeals rarely succeed.

MUE values for J0179 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services122 Date of Service Edit: PolicyAnatomic Consideration
Facility outpatient hospital122 Date of Service Edit: PolicyAnatomic Consideration

MUE for J0179 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J0179 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J0179 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J0179 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J0179 in their HCPCS tables, covering 5 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J0179
ArticleTitleContractor(s)StatesRelated LCD
A52451Billing and Coding: Ranibizumab, Aflibercept and biosimilarsWellpoint FederalCT IL MN NY WIL33394

Diagnoses Medicare contractors cover for J0179

One billing and coding article attaches a covered diagnosis list to J0179: 12 distinct ICD-10-CM codes in all. The 12 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 12 covered ICD-10-CM codes for J0179
ICD-10-CMDescription (FY2027)Articles covering
H35.3210Exudative age-related macular degeneration, right eye, stage unspecified1 of 1
H35.3211Exudative age-related macular degeneration, right eye, with active choroidal neovascularization1 of 1
H35.3212Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization1 of 1
H35.3213Exudative age-related macular degeneration, right eye, with inactive scar1 of 1
H35.3220Exudative age-related macular degeneration, left eye, stage unspecified1 of 1
H35.3221Exudative age-related macular degeneration, left eye, with active choroidal neovascularization1 of 1
H35.3222Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization1 of 1
H35.3223Exudative age-related macular degeneration, left eye, with inactive scar1 of 1
H35.3230Exudative age-related macular degeneration, bilateral, stage unspecified1 of 1
H35.3231Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization1 of 1
H35.3232Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization1 of 1
H35.3233Exudative age-related macular degeneration, bilateral, with inactive scar1 of 1

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J0179 are counted here: a group whose instructions name J0179, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J0179, by article
ArticleContractorGroups that applyCovered codes for J0179Full list
A52451Wellpoint Federalgroup 3 applies to J017912On LCD L33394

Local coverage policies that list J0179

1 active Local Coverage Determination lists J0179 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J0179 carries status indicator K and is assigned to APC 9340, with a published national unadjusted payment of $360.439. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J0179 carries payment indicator K2, which CMS defines as "Drugs, biologicals, and radiopharmaceuticals paid separately when provided integral to a surgical procedure on ASC list; payment based on OPPS rate". The national ASC payment is $360.44 per 1 MG, paid only when the drug is furnished integral to a covered surgical procedure.

Common denials for J0179 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J0179

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J0179

What does HCPCS code J0179 describe?

J0179 is defined by CMS as "Injection, brolucizumab-dbll, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J0179 a CPT code?

No. J0179 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as brolucizumab-dbll (Beovu); CPT codes are five-character codes maintained by the AMA. On a Part B claim J0179 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J0179 in October 2026?

The ASP-based payment limit is $360.439 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $359.713. Commercial payers use their own fee schedules.

How many units of J0179 can be billed per day?

The practitioner Medically Unlikely Edit is 12 units per date of service with adjudication indicator 2 (Date of Service Edit: Policy). MAI 2 edits are policy limits and are rarely overturned on appeal. CMS cites "Anatomic Consideration" as the rationale.

Which NDCs map to J0179?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Beovu (Novartis Pharmaceuticals Corporation). For example NDC 00078-0827-60 (package size 0.05) equals 6 billing units of J0179.

Does J0179 have NCCI bundling edits?

No active practitioner PTP pairs list J0179 as a column-1 or column-2 code in the v323r0 release.

Which Medicare coverage articles mention J0179?

1 current Billing and Coding Article in the Medicare Coverage Database lists J0179, covering 5 states: A52451 (Billing and Coding: Ranibizumab, Aflibercept and biosimilars).

What diagnosis codes support J0179?

One Medicare billing and coding article lists 12 covered ICD-10-CM codes for J0179, for example H35.3210 (Exudative age-related macular degeneration, right eye, stage unspecified); H35.3211 (Exudative age-related macular degeneration, right eye, with active choroidal neovascularization); H35.3212 (Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization); H35.3213 (Exudative age-related macular degeneration, right eye, with inactive scar); H35.3220 (Exudative age-related macular degeneration, left eye, stage unspecified). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.